UBS Maintains Buy on Cencora, Lowers Price Target to $400
UBS analyst Kevin Caliendo maintains Cencora (NYSE:COR) with a Buy and lowers the price target from $430 to $400.
Stocks · News reference
8-K filing — Cencora, Inc. (COR)
Filed: 2026-09-25 AccNo: 0001104659-26-110624 Size: 264 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie and Pfizer are compared as healthcare investment options in 2026. AbbVie has successfully navigated patent cliff challenges with strong growth from Skyrizi and Rinvoq offsetting Humira losses, while Pfizer is rebuilding its pipeline around obesity drugs and awaiting key pipeline readouts. The article recommends AbbVie as the clearer choice for investors seeking current pharmaceutical exposure, though both companies face biosimilar competition and regulatory pressures.
Cencora Q3 2026 Earnings Call Transcript
Cencora (NYSE:COR) held its third-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time access to our entire
Leerink Partners Maintains Outperform on Cencora, Raises Price Target to $388
Leerink Partners analyst Michael Cherny maintains Cencora (NYSE:COR) with a Outperform and raises the price target from $380 to $388.